Lyell Immunopharma Past Earnings Performance
Past criteria checks 0/6
Lyell Immunopharma's earnings have been declining at an average annual rate of -4.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 50.7% per year.
Key information
-4.4%
Earnings growth rate
104.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 50.7% |
| Return on equity | -35.8% |
| Net Margin | -180,486.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Apr 16Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Feb 23
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Nov 09Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher
Aug 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Aug 11Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans
Dec 15Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845
Oct 06Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Sep 12News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts
Aug 08Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Apr 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation
Sep 17Revenue & Expenses BreakdownBeta
How Lyell Immunopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -235 | 67 | 183 |
| 30 Sep 23 | 49 | -190 | 80 | 174 |
| 30 Jun 23 | 48 | -209 | 91 | 172 |
| 31 Mar 23 | 84 | -182 | 102 | 168 |
| 31 Dec 22 | 85 | -183 | 117 | 159 |
| 30 Sep 22 | 39 | -258 | 123 | 140 |
| 30 Jun 22 | 42 | -237 | 118 | 130 |
| 31 Mar 22 | 9 | -263 | 107 | 133 |
| 31 Dec 21 | 11 | -250 | 89 | 139 |
| 30 Sep 21 | 10 | -205 | 72 | 154 |
| 30 Jun 21 | 8 | -192 | 59 | 153 |
| 31 Mar 21 | 9 | -230 | 52 | 201 |
| 31 Dec 20 | 8 | -208 | 47 | 182 |
| 31 Dec 19 | 1 | -131 | 39 | 64 |
Quality Earnings: LYEL is currently unprofitable.
Growing Profit Margin: LYEL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LYEL is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare LYEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LYEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: LYEL has a negative Return on Equity (-35.82%), as it is currently unprofitable.